{"product_id":"generic-fionernone-lucifine","title":"LENVIDX-10 (Lenvatinib)","description":"\u003ch3\u003e\u003cspan id=\"About_Lenvatinib\"\u003eAbout Lenvatinib\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eLenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\u003c\/p\u003e\u003cp\u003e24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_everolimus\"\u003eCombination therapy with everolimus\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\n\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\n\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_pembrolizumab\"\u003eCombination therapy with pembrolizumab\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\n\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\n\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Dose_based_on_actual_body_weight\"\u003eDose based on actual body weight\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Endometrial_Cancer\"\u003eEndometrial Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\u003c\/p\u003e\u003cp\u003e20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eRefer to pembrolizumab prescribing information for recommended dosing information\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"DTC_dose_reductions\"\u003eDTC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"RCC_or_endometrial_carcinoma_dose_reductions\"\u003eRCC or endometrial carcinoma dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_everolimus_in_RCC\"\u003eDose modification of everolimus in RCC\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\n\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_pembrolizumab_in_endometrial_carcinoma\"\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\n\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\n\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"HCC_dose_reductions\"\u003eHCC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"First_occurrence\"\u003eFirst occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Second_occurrence\"\u003eSecond occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Third_occurrence\"\u003eThird occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hypertension\"\u003eHypertension\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Cardiac_dysfunction\"\u003eCardiac dysfunction\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Arterial_thrombotic_event\"\u003eArterial thrombotic event\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Proteinuria\"\u003eProteinuria\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\n\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"GI_toxicity\"\u003eGI toxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_failure_or_impairment\"\u003eRenal failure or impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Reversible_posterior_leukoencephalopathy_syndrome_RPLS\"\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_CrCl_30_mLmin\"\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_Child-Pugh_C\"\u003eSevere (Child-Pugh C)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949968427,"sku":"RL3020241018","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-0972-jpg.webp?v=1787022141","url":"https:\/\/xomeds.com\/products\/generic-fionernone-lucifine","provider":"XOMEDS","version":"1.0","type":"link"}